Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma

MonumenTAL-1: Long Term Follow up Efficacy

Videos

Larysa Sanchez, MD; and Samantha Shenoy, MSN, NP, discuss the management of adverse events with bispecific antibodies like GPRC5D and talquetamab while providing guidance on optimizing treatment outcomes and supportive care, as well as offering advice for managing toxicities and future perspectives on relapsed/refractory multiple myeloma.

Medical experts  give an overview of relapsed/refractory multiple myeloma, focusing on diagnosis and current management strategies

Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs

Experts give an overview of long-term follow-up efficacy data from the MonumenTAL-1 study.

Experts give an overview of safety data from the MonumenTAL-1 study.

MonumenTAL-1: Safety and AEs

Experts address the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer treatments, while Samantha will discuss strategies for preparing and educating patients undergoing GPRC5D therapy.

Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation

Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.

Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS 

Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, neurotoxicity, and hematological issues, and discuss how these are managed in practice.

Managing toxicities of BCMA_targeting Bispecfics

Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.

Management of Oral Toxcities associated with GPRC5D Bispecifics Nail

Experts provide advice to patients and caregivers on managing oral and skin toxicities.

Management of Skin and Nail AEs: Advice to Patients and Caregivers

Experts discuss prophylactic measures for managing potential adverse events associated with talquetamab and other bispecifics, while all faculty will offer advice for health care providers involved in the care of patients receiving talquetamab.

Prophylactic Strategies and Advice for Managing AEs in  Bispecific Therapies 

Experts provide advice for patients and caregivers with relapsed/refractory multiple myeloma considering talquetamab or another bispecific, while all faculty will discuss unmet needs and future perspectives in the treatment of relapsed/refractory multiple myeloma.

Unmet Needs and Future Perspectives on the treatment of R/R MM 

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

MonumenTAL-1: Long Term Follow up Efficacy

EP: 1.Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs

EP: 2.MonumenTAL-1: Long Term Follow up Efficacy

EP: 3.MonumenTAL-1: Safety and AEs

EP: 4.Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation

EP: 5.Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS

EP: 6.Managing toxicities of BCMA_targeting Bispecfics

EP: 7.Management of Oral Toxcities associated with GPRC5D Bispecifics Nail

EP: 8.Management of Skin and Nail AEs: Advice to Patients and Caregivers

EP: 9.Prophylactic Strategies and Advice for Managing AEs in Bispecific Therapies

EP: 10.Unmet Needs and Future Perspectives on the treatment of R/R MM

Newsletter